Menopause Accelerates Muscle Loss: What the Science Says About Hormones and Sarcopenia
A new narrative review maps how declining oestrogen during menopause disrupts muscle protein balance, accelerating sarcopenia risk in women.
Summary
This narrative review synthesizes evidence on how menopause and declining female sex hormones affect skeletal muscle mass and protein turnover. Across longitudinal and cross-sectional studies, women lose approximately 2.5% lean mass during perimenopause and 5.7% postmenopause compared to premenopausal peers. The perimenopause appears to be a critical window of accelerated muscle loss. Muscle protein synthesis (MPS) may be elevated at rest in older women but blunted in response to anabolic stimuli like resistance exercise and protein ingestion. Evidence on muscle protein breakdown (MPB) in humans is scarce, though animal and cell data suggest oestrogen suppresses MPB, meaning its decline post-menopause may tip the balance toward net muscle loss. The review calls for better measurement tools and targeted interventions.
Detailed Summary
Sarcopenia — the progressive age-related loss of muscle mass and strength — disproportionately affects women, with prevalence rising sharply between ages 40 and 60, precisely when menopause occurs. This narrative review from the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research at the University of Nottingham systematically evaluates human evidence linking menopause, female sex hormones, skeletal muscle mass, and muscle protein turnover.
The review analyzed 5 longitudinal and 11 cross-sectional studies on muscle or lean mass changes across the menopausal transition. Four of five longitudinal studies showed reductions in lean or muscle mass, with the rate of decline greatest during perimenopause — the transitional years immediately surrounding the final menstrual period. Cross-sectional data indicate perimenopausal women have approximately 2.5% less lean mass than premenopausal women, while postmenopausal women show roughly 5.7% less. Critically, most studies (10/11) relied on DXA-derived lean body mass, which incorporates body water, viscera, and connective tissue and may substantially overestimate true muscle mass, suggesting actual muscle losses could be even greater or differently distributed than reported.
On muscle protein turnover, the review assessed 7 studies measuring muscle protein synthesis (MPS). Basal MPS may actually be elevated in older versus younger women or age-matched men in some studies (3/7 and 4/5 respectively), possibly representing a compensatory response to anabolic resistance. However, the MPS response to resistance exercise was blunted in older women in 3 of 4 studies, and the response to protein ingestion was blunted in 3 of 6 studies, indicative of anabolic resistance that parallels findings in older men. Evidence directly measuring muscle protein breakdown (MPB) in humans across the menopausal transition is almost entirely absent, representing a major gap in the field.
Animal and cell-based evidence reviewed here consistently shows oestradiol suppresses proteolytic pathways including the ubiquitin-proteasome system, suggesting that post-menopausal oestrogen decline may increase MPB and shift the MPS:MPB balance toward net muscle loss. The role of progesterone, which declines earlier than oestrogen during perimenopause, and of FSH and LH elevations, is also discussed as potentially contributing to body composition changes. The authors highlight that hormone replacement therapy (HRT) and resistance exercise training remain the most promising interventions, but evidence specifically targeting muscle protein turnover outcomes remains thin.
The review concludes that perimenopause represents an underutilized intervention window. Future research should employ more sensitive muscle mass measurement tools such as methyl-D3-creatine dilution, measure both MPS and MPB simultaneously using stable isotope tracers, and design studies stratified by menopausal stage and hormone therapy status.
Key Findings
- Perimenopause is a window of accelerated lean mass loss: ~2.5% lower than premenopausal, rising to ~5.7% postmenopausally.
- Basal MPS may paradoxically be higher in older women, but anabolic responses to exercise and protein are blunted.
- Human evidence on muscle protein breakdown across menopause is nearly absent — a critical research gap.
- Animal/cell data suggest oestradiol suppresses proteolysis; its decline may increase MPB post-menopause.
- DXA underestimates true muscle loss; methyl-D3-creatine dilution is flagged as a superior measurement tool.
Methodology
This is a narrative review synthesizing longitudinal (n=5) and cross-sectional (n=11) human studies on muscle/lean mass across menopause, alongside studies measuring muscle protein synthesis (n=7) and limited protein breakdown data. Animal and cell model data were incorporated where human evidence was absent. No systematic search protocol or meta-analysis was performed.
Study Limitations
The review is narrative rather than systematic, introducing selection bias. The vast majority of muscle mass studies relied on DXA, which measures lean body mass rather than true muscle mass and may obscure actual changes. Evidence on muscle protein breakdown and on the specific hormonal mechanisms driving muscle loss in humans is largely absent, limiting causal conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
